Rohit Khanna Joins Intabio's Board of Directors

Brings Decades of Leadership Experience in Biopharmaceutical Analytical Instrumentation

NEWARK, Calif., Feb. 26, 2019 /PRNewswire/ -- Intabio, Inc. today announced the appointment of Rohit Khanna to its Board of Directors. In 2017, Dr. Khanna concluded a highly-successful career at Waters Corporation, where he most recently served as Senior Vice President and Corporate Officer with direct responsibility for over $1.1B in Waters' Applied Technology Businesses. Dr. Khanna will play a key role in guiding strategic partnerships and go-to-market planning as Intabio commercializes its first platform, the Blazeā„¢ system for blazingly fast product quality characterization of biotherapeutics.

Intabio, Inc. Logo (PRNewsfoto/Intabio, Inc.)

Dr. Khanna co-founded Dynamic Solutions in 1981, a scientific software company that pioneered automated system control and data analysis in the analytical industry. After Waters acquired Dynamic Solutions in 1986, Dr. Khanna spearheaded the creation of Waters' successful data product business, including the development of the industry-leading Empower platform. He transitioned to Vice President, Worldwide Marketing for Waters in 2002, leading product strategy, market development, brand and product management, and marketing communications. In this role, Dr. Khanna also managed a wide array of strategic partnerships and led several key technology acquisitions for Waters.

"Rohit is a true industry luminary who brings deep experience in corporate strategy and commercial operations as well as exceptional insight into Biopharma customer needs and strategic partnering opportunities with respect to the mass spectrometry industry," said Lena Wu, Intabio President and Chief Executive Officer. "We are honored to have Rohit join our Board of Directors as we develop our commercial system and prepare for the Blaze 1.0 launch in 2020."

"Intabio's innovative and unique analytical platform will deliver dramatic increases in throughput and productivity," added Dr. Khanna. "With the industry-wide focus on biologics, the opportunity for Intabio's technology to change the landscape for mass spectrometry from just a research tool to widespread adoption in biotherapeutic development and manufacturing is compelling, and I look forward to working closely with the Board in driving the success of this disruptive capability."

About Intabio

Intabio, Inc. is a Silicon Valley-based company developing analytical solutions to transform biotherapeutic development and manufacturing with products that provide early product quality characterization and profound efficiency gains across all stages of biopharmaceutical development and manufacturing. Intabio's first product, the Blaze system, is a microchip-based instrument system that will provide rapid detection and identification of subtle protein modifications - modifications that can undermine the stability and efficacy of biotherapeutic drugs such as monoclonal antibodies and recombinant proteins. For more information, please visit us at


Cision View original content to download multimedia:

SOURCE Intabio, Inc.

Back to news